Bleeding Risk in Pancreatic Biopsy

Introduction to Bleeding Risk

Mortality directly related to bleeding complications is extremely rare but has been reported (approximately 0.009-0.33%) 1

Coagulation abnormalities significantly increase bleeding risk, with INR >1.5 associated with a 7.1% bleeding risk compared to 1.1% with normal coagulation 1
Thrombocytopenia with platelet counts <150×10⁹/L increases bleeding risk (2.9% vs 1.6%) 1
Elevated bilirubin levels correlate with increased bleeding risk (2.7% vs 1.1%) 1
Renal dysfunction is strongly associated with bleeding complications, with studies showing significantly higher serum creatinine in patients who develop bleeding 2

For patients on direct oral anticoagulants (DOACs), the last dose should be taken 3 days before the procedure 3
For patients on warfarin, check INR one week before the procedure and ensure INR <1.5 before proceeding 3
Pre-procedure coagulation screening should include platelet count, PT/INR, and APTT 1
Address acute and/or chronic kidney dysfunction as much as possible before elective procedures 2

CEUS (contrast-enhanced ultrasound) guidance can increase biopsy success rates to 88-96% for lesions not visible on standard ultrasound 4

Close monitoring for signs of bleeding is essential in the first 2-4 hours after the procedure 1
Patients should be monitored for at least 3 hours after biopsy with regular clinical observations and measurement of blood pressure and pulse 1

For anticoagulated patients who develop bleeding, anticoagulation should be resumed up to 2-3 days after the procedure depending on the perceived hemorrhagic and thrombotic risks 3

Patients with a history of primary malignancy have a high yield from pancreatic biopsies (91% positive for malignancy) 4
Patients with chronic liver disease may have altered hemostasis that traditional coagulation tests do not accurately reflect 5
Patients should be advised that there is an increased risk of post-procedure hemorrhage if they are on antiplatelets or anticoagulants 3